Residency · Residency · Infectiousdisease

Urinary Tract Infections - Complicated and Catheter-Associated

Classification and Definitions

UTI Spectrum

The spectrum of urinary tract infections is defined by a classification system that guides both diagnostic and therapeutic decisions. Uncomplicated cystitis refers to a lower tract infection occurring in a non-pregnant, pre-menopausal woman with a normal urinary tract. Uncomplicated pyelonephritis describes an upper tract infection in the same population. Complicated UTI encompasses infections in patients with structural or functional urinary tract abnormalities, indwelling devices, immunocompromise, male sex, pregnancy, or renal transplant. Catheter-associated UTI is defined as a UTI occurring in a patient with an indwelling catheter in place for two or more days at the time of symptom onset, or within 48 hours of catheter removal. Catheter-associated asymptomatic bacteriuria, defined as bacteriuria in a catheterized patient without symptoms, should not be treated with antibiotics.

Epidemiology

Urinary tract infections are the most common bacterial infection, with 50 to 60 percent of women experiencing at least one UTI during their lifetime. Catheter-associated UTI accounts for 75 percent of healthcare-associated UTIs, with approximately 450,000 cases occurring annually in the United States. CAUTI has been designated by the Centers for Medicare and Medicaid Services as a "never event" that is no longer reimbursed as a hospital-acquired condition. Recurrent UTI, defined as two or more infections in six months or three or more in twelve months, affects 20 to 30 percent of women.

Microbiology

Common Pathogens

The microbiology of urinary tract infections shifts predictably along the spectrum from uncomplicated to complicated and catheter-associated disease. In uncomplicated UTI, E. coli dominates at 75 to 95 percent of cases, followed by Klebsiella at approximately 5 percent, Staphylococcus saprophyticus at 5 to 15 percent in young women, Proteus mirabilis, and Enterococcus. In complicated and catheter-associated UTIs, E. coli remains the most common pathogen but at a lower proportion of 40 to 50 percent, with Klebsiella, Proteus, Pseudomonas, Enterococcus, and Candida species assuming greater relative importance. ESBL-producing E. coli and Klebsiella are increasingly common in recurrent UTIs and healthcare-associated settings. Candida is commonly recovered from catheterized patients but usually represents colonization; treatment is warranted only when the patient is symptomatic or at high risk, such as those with neutropenia, renal transplant, or pre-urologic surgery.

Interpreting Urine Cultures

The traditional culture threshold of 10 to the fifth CFU per milliliter remains the standard, though counts of 10 to the third or above may be clinically significant in symptomatic women and catheterized patients. Pyuria, defined as 10 or more white blood cells per high-power field, supports a diagnosis of true infection rather than colonization, and the absence of pyuria strongly argues against UTI. Multiple organisms in a clean-catch specimen usually represent contamination, though polymicrobial results may be clinically significant in catheterized patients. S. saprophyticus is always clinically significant when isolated from a symptomatic young woman, even at lower colony counts.

Uncomplicated Cystitis

Diagnosis

Uncomplicated cystitis is a clinical diagnosis in symptomatic women presenting with dysuria, frequency, urgency, and suprapubic pain. Urine culture is not routinely needed and empiric treatment is appropriate. Cultures should be obtained when treatment fails, in recurrent infections, when resistant organisms are suspected, during pregnancy, or following recent healthcare exposure.

Treatment (IDSA 2011 Guidelines)

First-line therapy consists of nitrofurantoin monohydrate/macrocrystals at 100 milligrams orally twice daily for five days, trimethoprim-sulfamethoxazole double-strength orally twice daily for three days if local resistance is below 20 percent, or fosfomycin 3 grams orally as a single dose, though fosfomycin has inferior efficacy compared to the other two agents. Nitrofurantoin should be avoided when creatinine clearance falls below 30 milliliters per minute due to poor urinary concentration.

Second-line agents include fluoroquinolones, specifically ciprofloxacin 250 milligrams twice daily or levofloxacin 250 milligrams daily for three days, which should be reserved for complicated cases due to their significant adverse effect profile and collateral damage to the microbiome. Beta-lactams including amoxicillin-clavulanate, cefdinir, and cephalexin are considered third-line options due to inferior efficacy. Phenazopyridine 200 milligrams three times daily for two days provides symptomatic relief as a bladder analgesic, with patients counseled about the expected orange discoloration of urine.

Complicated UTI

Risk Factors for Complicated UTI

Factors that define a complicated UTI include structural abnormalities such as obstruction, stones, strictures, neurogenic bladder, or vesicoureteral reflux; the presence of an indwelling or intermittent catheter; male sex, as prostatic involvement renders these infections complicated by definition in many guidelines; pregnancy; renal transplant; immunocompromised states; and recent instrumentation or urologic surgery.

Diagnostic Approach

Urine culture with susceptibility testing is always required in complicated UTI. Blood cultures should be obtained when systemic signs are present, including fever and hemodynamic instability. Imaging with CT abdomen and pelvis with contrast or renal ultrasound is indicated when obstruction is suspected, when the patient fails to respond to therapy, or in recurrent infection. CT urogram provides the best evaluation for stone detection, abscess formation, and structural abnormalities.

Treatment

Empiric therapy pending cultures consists of ceftriaxone 1 gram intravenously daily, a fluoroquinolone if local susceptibility exceeds 90 percent, or piperacillin-tazobactam or meropenem for severe sepsis or patients with MDR risk factors. Duration is 7 to 14 days administered either orally or intravenously, though shorter courses of 5 to 7 days may be adequate for non-bacteremic complicated UTI. Oral step-down to a fluoroquinolone, trimethoprim-sulfamethoxazole, or an oral cephalosporin is guided by susceptibility data. For ESBL-producing organisms, carbapenems are indicated for severe infections including bacteremia, while oral options for cystitis include trimethoprim-sulfamethoxazole and nitrofurantoin if susceptible. Source control, including relief of obstruction, catheter removal or exchange, and abscess drainage, is essential.

<image>A clinical algorithm for management of complicated UTI. Start with "Suspected complicated UTI (fever, flank pain, dysuria in patient with risk factors)." First step: "Obtain urine culture + blood cultures + BMP." Second step: "Assess severity" with branches: "Mild-moderate (stable, tolerating PO)" leading to "Outpatient: oral fluoroquinolone or TMP-SMX x 7-14 days based on culture" and "Severe (sepsis, unable to tolerate PO, obstruction)" leading to "Admit: empiric IV ceftriaxone or pip-tazo (if MDR risk: meropenem) + imaging (CT or US)." For the severe pathway, add "Source control: relieve obstruction, remove catheter, drain abscess." Include a de-escalation box: "48-72 hours: narrow to targeted therapy based on culture; IV-to-PO switch when stable; total 7-14 days." Use a clinical flowchart format with severity-based color coding.</image>

Catheter-Associated UTI (CAUTI)

Pathogenesis

Biofilm forms on the catheter surface within 24 to 48 hours and becomes universal by 30 days of catheterization. The extraluminal route, in which organisms ascend between the catheter and the urethral mucosa, is the most common pathway. The intraluminal route, involving contamination of the drainage system and retrograde flow, is the secondary mechanism. The risk of developing bacteriuria is 3 to 8 percent per day of catheterization, and bacteriuria becomes nearly universal by 30 days.

Diagnosis

The diagnosis of CAUTI requires the presence of symptoms, which may include fever, rigors, altered mental status in the absence of another identifiable source, flank pain, costovertebral angle tenderness, hematuria, or pelvic discomfort. Catheter-associated bacteriuria without symptoms constitutes catheter-associated asymptomatic bacteriuria and should not be treated. Pyuria is not an indication for treatment in catheterized patients, as pyuria is universal in the presence of a catheter. The catheter should be replaced before obtaining the culture specimen, as the old catheter biofilm yields misleading results.

Treatment of CAUTI

The catheter should be removed or replaced as the first intervention, as this reduces both treatment failure and relapse. The culture specimen should be obtained from the newly placed catheter or from a midstream specimen after catheter removal. Duration of treatment is seven days if the patient responds promptly, ten to fourteen days if the response is delayed, and five days may be sufficient for women presenting with cystitis symptoms only, as supported by Drekonja's 2013 trial. For candiduria, catheter removal alone resolves the candiduria in 40 percent of cases; antifungal treatment with fluconazole 200 milligrams daily for 14 days is reserved for symptomatic patients, neutropenic patients, renal transplant recipients, and patients undergoing urologic procedures.

Prevention of CAUTI

The most important single intervention for CAUTI prevention is avoiding unnecessary catheterization and removing catheters promptly. Appropriate indications for indwelling urinary catheters include acute urinary retention or obstruction, accurate urine output monitoring in critically ill patients, selected perioperative settings, management of sacral or perineal wounds in incontinent patients, and comfort care in end-of-life situations. The CAUTI prevention bundle encompasses nurse-driven catheter removal protocols with daily assessment of catheter necessity, maintenance of a closed drainage system, securing the catheter to prevent traction, keeping the drainage bag below bladder level and emptying it regularly, and hand hygiene before and after catheter manipulation. Alternatives to indwelling catheters include intermittent catheterization, which carries a lower infection rate, condom catheters for males, and portable ultrasound bladder scanners. Antimicrobial-coated catheters with silver alloy or nitrofurazone produce modest short-term reductions in bacteriuria but have not been proven to reduce symptomatic CAUTI and are not routinely recommended.

<image>An infographic illustrating CAUTI prevention strategies arranged around a central image of an indwelling urinary catheter and drainage system. Around the catheter, show labeled prevention measures: "1. Avoid unnecessary catheterization (list appropriate indications)," "2. Daily reassessment for catheter removal (nurse-driven protocol)," "3. Maintain closed drainage system," "4. Keep bag below bladder level," "5. Hand hygiene before/after manipulation," "6. Secure catheter to prevent urethral trauma." Include statistics: "Risk of bacteriuria: 3-8% per catheter-day," "Catheter removal resolves bacteriuria in 40% of cases." Show a comparison box: "Alternatives: intermittent catheterization, condom catheter, bladder scanner." Use a clean, educational poster style with icons for each prevention measure.</image>

Asymptomatic Bacteriuria

When NOT to Treat

Asymptomatic bacteriuria should not be treated in elderly patients whether in the community or long-term care facilities, catheterized patients, patients with diabetes, patients with spinal cord injury, or patients undergoing pre-orthopedic surgery, though the latter remains controversial with most guidelines recommending against treatment.

When to Treat

Asymptomatic bacteriuria should be treated in two specific populations. Pregnant women should be screened at 12 to 16 weeks of gestation, as untreated bacteriuria carries a 20 to 40 percent incidence of progression to pyelonephritis and increases the risk of preterm labor. Treatment options include amoxicillin, cephalexin, or nitrofurantoin, with the caveats that trimethoprim-sulfamethoxazole should be avoided in the first trimester and nitrofurantoin should be avoided at term. The second population is patients preparing for urologic surgery involving mucosal breach, where treatment reduces the risk of post-procedural bacteremia.

Recurrent UTI in Women

Non-Antimicrobial Prevention

Non-antimicrobial strategies for preventing recurrent UTI encompass behavioral modifications, cranberry products, vaginal estrogen, D-mannose, and methenamine hippurate. Behavioral measures include adequate hydration and post-coital voiding, which has limited evidence but no associated harm, and avoidance of spermicides. Cranberry products provide a modest benefit in meta-analyses when consumed at 36 milligrams of proanthocyanidins daily. Vaginal estrogen in post-menopausal women reduces UTI recurrence by 50 to 70 percent and is one of the most effective non-antibiotic prevention strategies available, with intravaginal cream or ring formulations preferred. D-mannose at 2 grams daily shows emerging evidence of benefit through blocking type 1 fimbriae-mediated E. coli adhesion to the urothelium. Methenamine hippurate at 1 gram orally twice daily generates formaldehyde in acidic urine, and the ALTAR trial published in 2022 demonstrated non-inferiority to low-dose prophylactic antibiotics for recurrent UTI prevention, establishing it as a viable non-antibiotic alternative.

Antimicrobial Prophylaxis

When antimicrobial prophylaxis is necessary, options include continuous low-dose prophylaxis with nitrofurantoin 50 to 100 milligrams nightly, trimethoprim-sulfamethoxazole half-tablet nightly, or cephalexin 250 milligrams nightly for six to twelve months. Post-coital prophylaxis with a single dose of nitrofurantoin or trimethoprim-sulfamethoxazole after intercourse is effective in women with clear coital-related recurrences. Self-start therapy, in which the patient initiates a previously prescribed antibiotic course at symptom onset, is a practical option for motivated patients with reliable symptom recognition.

Key Clinical Pearls

• Treat the patient, not the culture -- asymptomatic bacteriuria should NOT be treated except in pregnancy and pre-urologic surgery
• Pyuria in catheterized patients is universal and is NOT an indication for antibiotics
• The single most important intervention for CAUTI prevention is removing unnecessary catheters -- nurse-driven removal protocols are highly effective
• Nitrofurantoin and TMP-SMX remain first-line for uncomplicated cystitis -- save fluoroquinolones for complicated infections
• Replace the catheter before culturing to avoid biofilm-associated false results
• Vaginal estrogen for post-menopausal recurrent UTI is one of the most effective non-antibiotic prevention strategies available
• Methenamine hippurate (ALTAR trial) is a viable non-antibiotic alternative for recurrent UTI prevention

References

1. Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women (IDSA 2011). Clin Infect Dis. 2011;52(5):e103-e120.
2. Hooton TM, Bradley SF, Cardenas DD, et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults (IDSA 2010). Clin Infect Dis. 2010;50(5):625-663.
3. Nicolle LE, Gupta K, Bradley SF, et al. Clinical practice guideline for the management of asymptomatic bacteriuria (IDSA 2019 update). Clin Infect Dis. 2019;68(10):e83-e110.
4. Harding C, Mossop H, Homer T, et al. Alternative to prophylactic antibiotics for the treatment of recurrent urinary tract infections in women (ALTAR). BMJ. 2022;376:e068229.
5. Tamma PD, Aitken SL, Bonomo RA, et al. IDSA 2023 guidance on the treatment of antimicrobial-resistant gram-negative infections. Clin Infect Dis. 2023.

Read this lecture as Markdown